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Introduction
 Aortic stenosis (AS) is the most prevalent primary heart 
valve disease [1] and the third most prevalent cardiovascu-
lar disease in the world, having a severe and slowly progres-
sive evolution [2]. This pathology is defined by firbro-calcif-
ic remodeling of the normal aortic valve (AoV) (tricuspid) 
or congenital abnormal AoV (biscupid), which results in 
the narrowing of the valve opening through a degenerative 
mechanism. Its evolution is specific for elderly patients, who 
have other comorbidities and is associated with progressive 
heart dysfunction. Patients with severe symptomatic AS, 
without any intervention, reach a fatal rate of about 50% at 2 
years and the only way to stop the progression to a terminal 
heart disease is valve replacement [2, 3].
A meta-analysis of studies conducted in Europe and 
USA concluded that the prevalence of AS is 12.4% among 
the population, and for those over the age of 75 years is 3.4% 
[4], so that more than 1 out of 8 people over the age of 75 
suffer from this pathology [5]. As the population ages, AS 
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Abstract
Background: Aortic stenosis (AS) is the most prevalent primary heart valve disease and the third most prevalent cardiovascular disease in the world, 
having a severe and slowly progressive evolution. The implementation of Transcatheter Aortic Valve Implantation (TAVI) is necessary because the 
population is constantly ageing, and most elderly people have various comorbidities, which places them among patients with high surgical risk. The aim 
was to report immediate and 9 months follow-up results of first TAVI implantations in the Republic of Moldova.
Material and methods: Three patients with severe symptomatic AS and high surgical risk underwent TAVI implantation using Portico valves.
Results: The mean age was 76.7 ± 1.2 years, 2 women and 1 man. The mean Logistic EuroSCORE II was 5.68 ± 0.67%. Procedural success was achieved 
in all (100%) patients. After the intervention, it was shown that the GP mean decreased by an average of 20.27±1.61 mmHg, the Vmax of the jet through 
AoV decreased on average by 2.05±0.19 m/s, and they were maintained all over the nine months follow-up period. Quality of life, using the TASQ (Toronto 
Aortic Stenosis Quality of Life) questionnaire, was improved by 62.3 ± 2.2 points.
Conclusions: TAVI, as a new minimally invasive method of treatment for aortic valve stenosis appears to be safe, with a low rate of early and late 
complications in elderly patients at high surgical risk, with good clinical outcomes at 9 months. Its implementation in the Republic of Moldova is welcome 
in the conditions of continuously ageing population and the prevalence of associated comorbidities.
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becomes an important issue both in terms of declining pa-
tients’ quality of life and in terms of the impact on the health 
care system [5].
Until recently, the golden standard and the only solution 
in treating AS was surgical aortic valve replacement (SAVR). 
However, the risks associated with SAVR are increased in 
elderly patients and those with severe systolic heart failure 
or concomitant coronary heart disease, as well as in patients 
with comorbidities such as cerebrovascular and peripheral 
arterial disease, chronic renal disease and chronic respira-
tory failure. Approximately one third of the patients with 
AS are inoperable or have a high surgical risk with the SAVR 
method [5, 6].
Thus, in 2002, Alain Cribier came up with an alter-
native for the replacement of stenotic AoV, namely the 
Transcatheter Aortic Valve Implantation (TAVI) [7]. The in-
troduction of the new method of treatment has revolution-
ized the management of aortic stenosis [8]. Several studies, 
where first-generation devices have been used, have estab-
lished the superiority of TAVI compared to medical therapy 
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Table 1
Indications for aortic stenosis interventions and the recommendations  
for choosing the type of intervention [1].
Symptomatic patients with aortic stenosis Class Level 
The intervention is indicated for symptomatic patients with severe aortic stenosis, severe high gradient 
(AV Vmax >4 m/s or mean gradient >40 mm Hg)
I B
Indicated in patients with low-flow low-gradient severe AS (<40 mmHg) with reduced ejection fraction and evidence of 
contractile reserve excluding pseudo-severe AS. I C
Intervention should be considered in patients with symptomatic low-flow low-gradient severe AS (<40 mmHg), with 
preserved ejection fraction, after careful confirmation of severe AS. IIa C
Intervention should be considered in patients with low-flow low-gradient severe AS with reduced ejection fraction 
without evidence of contractile reserve especially where CT calcium scoring confirms severe AS. IIa C
that includes valvuloplasty in patients at high surgical risk 
[8]. Subsequently, TAVI has been proposed as a valuable al-
ternative to SAVR in an ever-widening spectrum of patients 
with severe symptomatic AS. The safety and efficacy of 
TAVI were initially established in high surgical risk patients 
in the PARTNER Study 1A, US CoreValve High-risk Trial 
who presented comparable clinical results [9] non-inferior 
to SAVR [8, 10].
This intervention is minimally invasive and is based on 
the percutaneous implantation of a self-expanding AoV 
prosthesis, replacing the dysfunctional native valve, through 
a catheter, using transfemoral approach (also the transapical 
or transaortic approach might be considered). Due to the 
indications of TAVI, this represents an excellent opportu-
nity for patients with an increased or intermediate surgical 
risk, or those who are inoperable [11]. The basic indications 
for TAVI, respecting the clinical aspects, would be STS / 
EuroSCORE II > 4%, presence of severe comorbidities, age 
> 75 years, previously undergone cardiac surgery, patient 
fragility which is associated with increased morbidity and 
mortality after surgery and TAVI, reduced motility and con-
ditions that would affect the post-procedural rehabilitation 
process. Also, the anatomical aspects of the patients are tak-
en into account, first of all a favorable transfemoral access 
for TAVI, porcelain aorta, the presence of coronary bypass 
with previous sternotomy, possible patient-prosthesis mis-
match, severe thoracic deformities, post-radiation thoracic 
sequelae (tab. 1) [1].
At this stage, companies producing new-generation 
TAVI devices are developing important technological re-
finements, including reduced size delivery systems, trying 
to avoid or minimize paravalvular leakage. Broadly speak-
ing, for clinical use, there are two main categories of AoV 
transcatheter prostheses: balloon-expandable valves and 
self-expandable valves [8].
The Portico Valve System (St. Jude Medical; Minneapolis, 
Minnesota, USA) is a second-generation transcatheter AoV, 
a self-expandable prosthesis that consists of a trifoliate bo-
vine pericardial valve and a porcine pericardial sealing cuff 
attached to a nitinol frame, all meant to reduce paraval-
vular leakage. The delivery system allows full resheathing 
and repositioning prior to complete valve deployment un-
til 80-90% of deployment, which is potentially one of the 
most important advantages of this transcatheter heart valve. 
At this stage, the annular section of the prosthesis has full 
contact, allowing the assessment of placement and hemo-
dynamic function before its final release. In addition, the 
leaflets are designed to function at an intra-annular aortic 
position, which helps maintain hemodynamic stability dur-
ing implantation [12].
As a result of a fruitful collaboration with the specialists 
of the University Hospital of Frankfurt, in October 2019, as 
a premiere for the Republic of Moldova, transcatheter AoV 
prostheses were implanted. Being the first team of doctors 
who performed TAVI in our country, we have the oppor-
tunity to report the data of a series of cases, with clinical 
follow-up at 9 months after the procedure. 
Material and methods
I.  The team
The team consisted of two cardiologists, a cardiovascu-
lar surgeon, an anesthesiologist and an echocardiographist. 
Interventional cardiologists underwent a training program 
in the University Hospital of Frankfurt. The first three cases 
were performed under the supervision of Doctor Mariuca 
Vasa-Nicotera, Frankfurt, Germany.
II.  The patients
The first patients to benefit from the procedure were 2 
women and a man, the mean age was 76.7 ± 1.2 years, with 
a severe degree of AoV calcification, who could not under-
go SAVR due to the high surgical risk. Patients underwent 
coronary angiography, echocardiography and computed to-
mography to determine the coronary blood flow, structural 
cardiac parameters, AoV size and the surgical approach.
Patient no 1, woman, 79 years old.
She was admitted with severe AS documented follo-
wing M-mode and two-dimensional echocardiography, 
with a mean pressure gradient of 58.33 mmHg and a maxi-
mal jet velocity through the AoV of 5.06 m/s, moderate 
AoV regurgitation, marked left ventricular (LV) myocar-
dial hypertrophy with accelerated flow in the LV outflow 
tract, ejection fraction being 59% (fig. 1). On computed 
tomography was determined aortic valve with an annulus 
perimeter of 68.8 mm, its area of 363.8 mm2, and a diameter 
of 21.5 mm (fig. 2). Also, the patient had a porcelain aorta 
(fig. 3). Coronary angiography revealed no stenotic lesions 
60
ORIGINAL  ReseARchM. Abras et al. Moldovan Medical Journal. September 2020;63(3):58-65
of the coronary arteries (fig 5, 6). Calculated in advance, the 
patient had an Euroscore II of 6.14%. 
The size of the selected valve, according to the above 
parameters, was 25 mm. After analysing the anatomical as-
pects of the iliac and femoral arteries (fig. 4), the approach 
for intervention was chosen, namely the right femoral one.
Patient no 2, man, 76 years old.
At admission, he presented with severe AS and several 
comorbidities such as dyslipidemia, type 2 diabetes, chronic 
bronchitis in partial remission, left renal cysts, right eye 
blindness, obesity class II, discirculatory encephalopathy. 
Euroscore II calculated was 6.53%.
Following M-mode and two-dimensional real-time car-
diac ultrasonography, AoV critical stenosis was determined 
with a mean pressure gradient at the aortic valve of 36.57 
mmHg, the maximal aortic jet velocity being 3.84 m/s and 
the ejection fraction of the left ventricle 36% (fig. 7). The 
computed tomography showed an aortic valve annulus with 
a diameter of 24.7 mm, an area of 450.5 mm2 and a perime-
ter of 77.9 mm (fig. 8, 9). Coronary angiography did not de-
Fig. 1.  Echocardiography, patient no 1 Fig. 2.  CT of aortic valve, patient no 1
Fig. 3.  CT, porcelain aorta, patient no 1 Fig. 4.  CT, iliac arteries, patient no 1
Fig. 5.  Coronarography, patient no 1 Fig. 6.  Coronarography, patient no 1.
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Fig. 7.  Echocardiography, patient no 2 Fig. 8.  CT aortic valve, patient no 2
Fig. 9.  CT, aorta, patient no 2 Fig. 10.  CT, iliac arteries, patient no 2
Fig. 11.  Left carotid artery angiography, 
patient no 2
Fig. 12.  Left internal carotid artery 
angiography, after angioplasty
termine stenoses on the coronary arteries but revealed criti-
cal stenosis with the appearance of unstable plaque on the 
left internal carotid artery (fig. 11). Two weeks before the 
procedure, the patient successfully underwent carotid angi-
oplasty with self-expanding stent implantation (PROTEGE 
Rx) (fig. 12).
According to these data, the size of the valve should be 
27 mm, but due to ellipticity of the valve, a 29 mm one was 
chosen. The geometric construction of the valve allows it 
to shape itself to various anatomical variations, but also to 
easily attach to the calcifications of the native valve, without 
deforming the nitinol frame. Analysing the anatomical as-
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pect of the iliac and femoral arteries (fig. 10), it was decided 
to select the approach for intervention – the left femoral.
Patient no 3, woman, 75 years old.
The patient was admitted with diagnosis of severe AS, 
left bundle branch block, permanent atrial fibrillation, high 
thromboembolic risk (CHADS VASc = 6), NYHA class III 
heart failure, stage III hypertension, very high additional 
risk, dyslipidemia, ischemic stroke endured in 2015. Eu-
roscore II, calculated, was 4.36%. Following M-mode and 
two-dimensional real-time cardiac ultrasonography, severe 
AS with a mean pressure gradient of 40.71mmHg was deter-
mined, the maximal jet velocity at AoV level being 4, 16 m 
/ s, mild AoV insufficiency, moderate mitral valve and tri-
cuspid valve insufficiency, ejection fraction of 55% (fig. 13).
On the computed tomography, the aortic valve annulus 
has a perimeter of 73.6 mm, an area of 419.5 mm2, and a di-
ameter of 23.2 mm (fig. 14, 15). Coronary angiography does 
not determine stenotic lesions of the coronary arteries (fig. 
17, 18). Analysing the above data, it was decided to implant 
a 27 mm valve. Examining the anatomical aspect of the iliac 
and femoral arteries (fig. 16), it was decided to select the ap-
proach for the intervention, right femoral artery.
I.  Devices
Portico prosthetic valves, which were used for all 3 
patients, consist of a self-expandable nitinol frame, with 
rhomboid spaces in which pericardial tissue of bovine or 
porcine origin is arranged, with an available diameter of 23 
to 29 mm (tab. 2). This valve undergoes a Linx AC (anti-
calcification) treatment, based on ethanol, which has been 
shown to be effective in reducing the calcification in ani-
mal tissues [12]. The mandatory component of the valve is a 
flexible and easy-to-navigate Portico delivery system, which 
has an 18Fr / 19Fr (6.0 / 6.5 mm) delivery sheath.
Table 2









23 mm 19-21 277-346 60-66
25 mm 21-23 338-415 66-73
27 mm 23-25 405-491 72-79
29 mm 25-27 479-573 79-85
Fig. 13.  Echocardiography, patient no 3 Fig. 14.  CT of the aortic valve, patient no 3
Fig. 15.  CT of aorta, patient no 3 Fig. 16.  Iliac arteries CT, patient no 3
63
ORIGINAL  ReseARch M. Abras et al. Moldovan Medical Journal. September 2020;63(3):58-65
II.  The procedure
Patients were given clopidogrel and aspirin prior to in-
tervention, immediately before the procedure – antibiotics 
for the prophylaxis of potential infections, and unfraction-
ated heparin (100 U/kg) throughout the procedure. All 
three patients underwent general anaesthesia.
The minimally invasive intervention was performed in 
a cardiac catheterization room, in sterile conditions. In all 
3 cases, the transfemoral approach was used, the femoral 
artery being cannulated using the Seldinger technique with 
placement of the femoral sheath on the contralateral side, a 
femoral access was obtained for aortic angiography. Also, a 
venous access was made for a temporary pacemaker, later 
used for rapid ventricular pacing, its proper placement be-
ing verified by a rapid ventricular pacing test at the rate of 
200 beats per minute. At the same time, the angiography 
of the aorta was made, choosing the optimal projection in 
which all the aortic cusps are aligned. Through the femoral 
artery, the valve delivery sheath was inserted (18F for the 
25 mm valve, and 19F for the 27 mm and 29 mm valves). 
A left Amplatz catheter (AL) on a J-shaped tip guidewire 
was used to pass the arch of aorta, then this guidewire was 
changed to a straight-tipped one, the native aortic valve be-
ing crossed through the non-coronary cusp, then advancing 
the AL catheter into the left ventricle. To avoid perforation 
of the ventricle, the AL was changed on a pigtail catheter, 
and the straight guidewire, again, on a J-shaped type.
During a rapid ventricular pacing, 200 rpm, under fluor-
oscopic guidance, balloon valvuloplasty was performed (fig. 
17), its role being in cracking the calcifications of the affect-
ed valve. After removing the balloon, the prosthetic valve 
and its delivery system were inserted through the delivery 
sheath, advanced through the descending aorta, carefully 
crossing the aortic arch, then the ascending aorta. Again, 
under fluoroscopic guidance, the valve was positioned ac-
cordingly (fig. 18). Rapid ventricular pacing was initiated, 
and when systolic pressure reached its lowest level, the aor-
tic valve was expanded (fig. 19). 
At the next stage, the pacing was stopped and a repeated 
angiography and echocardiography were performed, so that 
the good functionality of the valve and the lack of paravalvu-
lar regurgitation might be appreciated. Subsequently, it pro-
ceeded to the stage of releasing the valve from the delivery 
system. One by one, the delivery system, the catheter and 
the delivery sheath were removed. At the time of removal, 
blood pressure was carefully monitored, with simultaneous 
injection of contrast, to rule out a possible vascular rupture.
Hemostasis after femoral arteriotomy was performed 
using the Perclose ProGlide occlusion system. After TAVI, 
patients had to take clopidogrel for 6 months, and aspirin 
for indefinite amount of time.
Echocardiography follow-ups were performed immedi-
ately after the procedure, at 24h, 1 week, 1 month, 3 months, 
6 months and 9 months after implantation.
Quality of life (QoL) is an important consideration for 
aortic stenosis patients. The TASQ is questionnaire (Toron-
to Aortic Stenosis Quality of Life), is a QoL tool that was de-
veloped to evaluate the psychometric properties of patients 
who underwent TAVI.  TASQ is a questionnaire of 16 items, 
with 4 subdivisions, namely: symptoms – 2 items, physical 
limitations – 4 items, emotional impact – 7 items, social 
limitations – 2 items and one item that reflects health ex-
pectations. For each item, patients should expose the impact 
of aortic stenosis on their quality of life scale anchored by 
“not very much” – 1 point, to “very much” – 7 points. Total 
scores can range from 16 to 112, with the highest reflecting a 
better quality of life [13]. The patients respond at this ques-
tionnaire before the intervention and at 9 months after it.
Results
Procedure results and complications
Procedural success was achieved among all (100%) 
patients included in this case series analysis. All patients 
underwent the procedure through the femoral approach, 
which was afterwards sutured using Perclose ProGlide de-
vice, without any further complications at the puncture site. 
Patient No 2 developed a complete atrioventricular block 
after the placement of the valvular prosthesis and needed 
a permanent cardiac stimulator to be implanted. Other pe-
culiarities during the performance of TAVI did not inter-
fere and no serious complications occurred in the recovery 
process of the patients (tab. 3). The average length of the 
hospital stay was 6 days.
Following TAVI, in all 3 patients who benefited from 
the intervention, the functional parameters of the heart 
improved considerably. Post-procedurally, the ventriculog-
Fig. 17. Balloon valvuloplasty Fig. 18. Prosthetic valve positioning Fig. 19. Expanded prosthetic valve
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raphy showed normal transvalvular flow at the AoV level, 




Aortic regurgitation  > grade I 1/3





Left ventricular perforation 0/3
Permanent pacemaker 1/3
Vascular complications in trans-femoral approach 0/3
Transient ischemic attack 0/3
Procedure-related death 0/3
One week after the intervention, following a repeated 
echocardiography, it was shown that the GP mean de-
creased by an average of 20.27±1.61 mmHg, the Vmax of 
the jet through AoV decreased on average by 2.05±0.19 m/s, 
with an aortic orifice, obviously of a normal size. At nine 
month the GP mean decreased by an average of 28.4±3.21 
mmHg, the Vmax of the jet through AoV decreased on av-
erage by 2.32±0.03 m/s in patient 1, a mild paravalvular leak 
was found, but without any symptoms (tab. 4).
Quality of life was assessed using the TASQ (Toronto 
Aortic Stenosis Quality of Life) questionnaire. We can men-
tion a growth in the perception of quality of life in patient  1 
from 30 to 95 points, in patient 2 from 34 to 98 points and 
in patient 3 from 38 to 96.
Discussion
This first experience in the Republic of Moldova, regard-
ing TAVI, gives results similar to the ones from other studies 
and centres with experience in performing these minimally 
invasive interventions [8, 12]. The success rate depends on a 
good training of the team, adequate selection of the patients 
and the proper choice of the valve prosthesis, as well as the 
careful supervision of an experienced proctor.
Until the implementation of TAVI in the Republic of 
Moldova, experience in minimally invasive approach on 
aortic pathology was only in the case of aortic coarctation 
[14]. The large number of patients with severe AS over the 
age of 75, with multiple comorbidities and high surgical 
risk, to whom the replacement of the valve by surgery is of-
ten refused, imposed the need to implement these interven-
tions in the Republic of Moldova.
The Portico TAVI system study demonstrates that the 
treatment of elderly patients, with severe AS, using the full 
range of sizes of self-expandable, resheathable, reposition-
able and retrievable Portico valves leads to significant im-
provements in aortic valve function at 1 year. Importantly, 
the improvement was observed in the presence of a low rate 
of paravalvular regurgitation and new pacemakers implan-
tations [12] similar to the results obtained in our patients. 
Conduction disorders that require implantation of a perma-
nent pacemaker after TAVI are generally more common in 
patients who have implanted self-expanding transcatheter 
valves compared to those who have balloon-expandable 
devices. A large US registry reported a 30-day permanent 
pacemaker implantation rate of 25.1% among patients who 
received a Portico self-expanding valve, that is in line with 
pacemaker implantation rates reported for other TAVI self-
expanding devices (22%-26%) [15].
Adequate hemodynamic performance was observed by 
echocardiographic evaluation, with stable hemodynamic 
characteristics between 30 days and 1 year of follow-up. 
Paravalvular regurgitation is a rare phenomenon, due to 
the better patient selection, using multidetector computed 
tomography system, continuous increasing of experience 
among the operators and the possibility of repositioning the 
device. No patients reported severe paravalvular regurgita-
tion at one-year follow-up [8].
The symptoms associated with AS can lead to a much 
diminished quality of life, interfering in the patient's ability 
to integrate into normal daily activities but also in relation-
ships with other people. Understanding the effect of the pa-
thology on the patient's life is an essential step in planning 
the proper treatment that will optimize the management 
Table 4
Survival, symptomatic (nYHA) and echocardiographic data, compared over time
Patient 1 Patient 2 Patient 3
IF PP 9M IF PP 9M IF PP 9M
Survival + + + + + + + + +
NYHA class III II II III II II III II II
AVA (mm2) 363.8 NA NA 450.5 NA** NA 419.5 NA NA
MPG (mmHg) 58.33 36.0 23.6 36.57 16.4 12.3 40.71 22.4 14.5
Peak velocity (m/s) 5.06 3.0 2.7 3.84 1.6 1.5 4.16 2.3 1.9  
Annulus (mm) 21.5 NA NA 24.7 NA NA 23.2 NA
Ejection fraction 59% 62% 62% 36% 44% 48% 55% 63% 63%
AR grade II II II II II II I I I
*IF – initial features, PP – post-procedural, 9M – 9 months after the procedure, **NA – Non-appreciable,
AVA – aortic valve area, MPG – mean aortic valve pressure gradient, AR grade – grade of aortic valve insufficiency.
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of the pathology and the quality of the results. Comparing 
the patients' responses before the intervention with those at 
9 months after it, we can say with certainty that TAVI has 
changed their perception of life, giving them both satisfac-
tion and hope to live as long as possible.
The implementation of TAVI in the Republic of Moldova 
is necessary because we can say that the population is con-
stantly aging, and most elderly people have various comor-
bidities, which place them among patients with high surgi-
cal risk. This method is a minimally invasive alternative that 
gives us predictable and reproducible results, progressively 
becoming safe and effective. A multidisciplinary team ap-
proach is recommended in the management of the patients 
with AS, because the decisions that should be taken in this 
pathology are very complex [1].
However, the high costs of this intervention and the lim-
ited financial resources available in a developing country are 
the main impediments to the widespread application of this 
new method of treating AS in the Republic of Moldova.
Conclusions
Transcatheter aortic valve implantation, as a new mini-
mally invasive method of treatment for aortic valve stenosis 
appears to be safe, with a low rate of early and late compli-
cations in elderly patients at high surgical risk, with good 
clinical outcomes at 9 months. Its implementation in the 
Republic of Moldova is welcome in the conditions of con-
tinuously aging population and the prevalence of associated 
comorbidities.
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